Mylan Seeks Licensing Partner, Heart Failure Indication For Nebivolol
This article was originally published in The Pink Sheet Daily
Executive Summary
The company hopes to announce a partner for nebivolol this fall, roughly the same timeframe targeted for discussions with FDA on data needed for a congestive heart failure claim. The beta blocker is “approvable” at FDA for hypertension; Mylan expects to respond to the agency by year-end.
You may also be interested in...
Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
Mylan's Nebivolol Is "Approvable" At FDA
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.